Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QHRD102
- Development stage
- Phase 1
- Lead developer
- Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
QHRD102 is an investigational anti-CD27 monoclonal antibody developed as a novel immunotherapeutic agent. It functions as a CD27 inhibitor and is being studied for its potential to treat hematological malignancies, specifically relapsed or refractory acute lymphoblastic leukemia (ALL) and extranodal NK/T-cell lymphoma (ENKTL). The drug is administered via intramuscular injection. Clinical trials are ongoing in China to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy in these patient populations[1][4].
02
Targets
CD27 (Cluster of Differentiation 27)
Beyond the preview
Go deeper on QHRD102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QHRD102.